Supplement Table 5. Severity change in patient self-assessed global clinical status after 4-day of treatment.

	Tolvaptan (N = 46)	Placebo (N = 45)	p value
Patient self-assessed global clinical status
Baseline
Mean	51.4 ± 23.6	50.0 ± 21.1	0.7789
End of study
Mean	69.8 ± 28.2	73.3 ± 19.5
Mean change from baseline	18.26 ± 23.89	23.32 ± 25.42	0.3536
Patient self-assessed dyspnea
Status at baseline, n (%)			0.8243*
Yes	30 (65.2%)	31 (68.9%)
No	16 (34.8%)	14 (31.1%)
Change from baseline at end of study, n (%)			0.7717
Markedly better	9 (19.6%)	8 (17.8%)
Moderately better	19 (41.3%)	19 (42.2%)
Minimally better	13 (28.3%)	9 (20.0%)
No change	3 (6.5%)	9 (20.0%)
Moderately worse	2 (4.3%)	0 (0.0%)

Definition: End of study, the data measured at the post-dosing examination visit after 4-day treatment.

p value: pair t-test for intragroup comparison; Post-Baseline ANCOVA Model was used in patient self-assessed global clinical status: outcome = treatment + baseline level; proportional odds model at Post-Baseline Visit was used in patient self-assessed dyspnea: outcome = treatment + baseline level (ordinal).

* The p value was tested by Fisher’s Exact Test.